This protocol addresses acute tubulointerstitial nephritis (ATIN) that develops as a complication of immune checkpoint inhibitor therapy. ATIN associated with ICPIs typically develops approximately 14 weeks after initiation of treatment, though onset can range considerably — from around 6 to 37 weeks after starting therapy.
Management centres on corticosteroid therapy as the cornerstone intervention. In the context of ICPI-associated ATIN, treatment duration considerations differ from standard ATIN management.
The primary aim is improvement in kidney function, with the target of complete or partial renal recovery. Most patients show measurable clinical improvement following therapy, though mild kidney impairment may persist beyond the acute phase.
DOI: 10.1016/j.ekir.2025.03.050
ATIN associated with ICPIs typically develops approximately 14 weeks (range: 6–37 weeks) after the initiation of treatment.
Corticosteroids remain the cornerstone of ATIN treatment, typically initiated with oral prednisolone or prednisone. An exception exists for ICPI-associated ATIN, where treatment may extend to 3 to 6 months.
Following therapy, most patients (64%) show clinical improvement with either complete or partial renal recovery, although mild kidney impairment persists at 12 months.
View source ↗